Lyndsay Young
Has grant
Research Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Aberrant Glycogen Modulates Metabolism in Ewing’s Sarcoma
Open Date: 2021-08-01
Close Date: 2023-08-01
Articles (12)
Year:
2026
Statistical analysis of detected N-glycans in each category of TMA. A, PCA score plot of all 152 N-glycans. B, PLS-DA plot and corresponding importance feature plot. C, t test plot of NED vs. MET with structures shown for the top 10 most significant peaks. D, Pattern search graph showing the top 25 peaks correlated with 2905.0368 (Hex8dHex1HexNAc7), m / z values of N-glycans with at least one or more fucose shown in red boxes. VIP, variable importance in projection.
Year:
2025
Analysis of collagen/ECM profile of NED vs. MET cohort from data obtained by LC-MS/MS. A, Pie chart representations of abundance (peak intensity and number of peptides identified via LC-MS/MS) of all detected protein species within the MET cohort. B, Pie chart representations of abundance of all detected protein species within the NED cohort.
Year:
2025
Statistical analysis of detected N-glycans in each category of TMA following EndoF3 and PNGaseF digestion. A, t test plot of detected N-glycans following EndoF3 digestion. Structures shown for top 10 most significant N-glycans ( B ) t test plot of detected N-glycans following PNGaseF digestion. Structures shown for top 10 most significant N-glycans C, Left-Right: PCA, PLS-DA plots for detected N-glycans following EndoF3 digestion. ROC curve showing NED vs. MET after EndoF3 digestion D, Left-Right: PCA, PLS-DA plots for detected N-glycans following PNGaseF digestion. ROC curve showing NED vs. Mets after PNGaseF digestion.
Year:
2025
Prostate cancer is a significant health concern, with metastasis posing major clinical challenges and resulting in poor patient outcome. Despite screening and treatment advances, a critical need for novel biomarkers to predict prostate cancer progression at the time of prostatectomy persists. Here, we assessed aberrant N-glycosylation patterns and alterations in extracellular matrix (ECM) proteins as potential biomarkers of predicting prostate cancer severity in a unique patient outcome cohort. Tissue microarray slides were assembled from primary prostatectomy specimens that were categorized into “no evidence of disease (NED)” and “metastasis (MET)” designations based on >5-year disease progression outcomes. Serial mass spectrometry imaging techniques were performed to analyze N-glycans and ECM components in formalin-fixed paraffin-embedded cores. The results revealed a significant upregulation of bisecting and multiantennary core-fucosylated N-glycans in MET tissues when compared with NED tissues. Alterations in ECM composition in both NED and MET cohorts were observed, particularly in collagen species and the amount of hydroxyproline content. Results suggest a coordinated alteration of ECM protein and glycosylation content in prostate cancer tissues can be predictive for postprostatectomy disease progression. Significance: Using matrix-assisted laser desorption/ionization mass spectrometry imaging techniques on a unique cohort of prostate cancer tissues, we highlighted several molecular characteristics of matrix that have potential to act as early predictors of prostate cancer metastasis.
Year:
2025
Glycogen synthase 1 (GYS1), the rate-limiting enzyme in muscle glycogen synthesis, plays a central role in energy homeostasis and has been proposed as a therapeutic target in multiple glycogen storage diseases. Despite decades of investigation, there are no known potent, selective small-molecule inhibitors of this enzyme. Here, we report the preclinical characterization of MZ-101, a small molecule that potently inhibits GYS1 in vitro and in vivo without inhibiting GYS2, a related isoform essential for synthesizing liver glycogen. Chronic treatment with MZ-101 depleted muscle glycogen and was well tolerated in mice. Pompe disease, a glycogen storage disease caused by mutations in acid α glucosidase (GAA), results in pathological accumulation of glycogen and consequent autophagolysosomal abnormalities, metabolic dysregulation, and muscle atrophy. Enzyme replacement therapy (ERT) with recombinant GAA is the only approved treatment for Pompe disease, but it requires frequent infusions, and efficacy is limited by suboptimal skeletal muscle distribution. In a mouse model of Pompe disease, chronic oral administration of MZ-101 alone reduced glycogen buildup in skeletal muscle with comparable efficacy to ERT. In addition, treatment with MZ-101 in combination with ERT had an additive effect and could normalize muscle glycogen concentrations. Biochemical, metabolomic, and transcriptomic analyses of muscle tissue demonstrated that lowering of glycogen concentrations with MZ-101, alone or in combination with ERT, corrected the cellular pathology in this mouse model. These data suggest that substrate reduction therapy with GYS1 inhibition may be a promising therapeutic approach for Pompe disease and other glycogen storage diseases.
Year:
2024
Prostate cancer is a significant health concern, with metastasis posing major clinical challenges and resulting in poor patient outcome. Despite screening and treatment advances, a critical need for novel biomarkers to predict prostate cancer progression at the time of prostatectomy persists. Here, we assessed aberrant N-glycosylation patterns and alterations in extracellular matrix (ECM) proteins as potential biomarkers of predicting prostate cancer severity in a unique patient outcome cohort. Tissue microarray slides were assembled from primary prostatectomy specimens that were categorized into “no evidence of disease (NED)” and “metastasis (MET)” designations based on >5-year disease progression outcomes. Serial mass spectrometry imaging techniques were performed to analyze N-glycans and ECM components in formalin-fixed paraffin-embedded cores. The results revealed a significant upregulation of bisecting and multiantennary core-fucosylated N-glycans in MET tissues when compared with NED tissues. Alterations in ECM composition in both NED and MET cohorts were observed, particularly in collagen species and the amount of hydroxyproline content. Results suggest a coordinated alteration of ECM protein and glycosylation content in prostate cancer tissues can be predictive for postprostatectomy disease progression. Significance: Using matrix-assisted laser desorption/ionization mass spectrometry imaging techniques on a unique cohort of prostate cancer tissues, we highlighted several molecular characteristics of matrix that have potential to act as early predictors of prostate cancer metastasis.
Year:
2024
Clinical characteristics for each patient in the cohort. There were 51 patients in the “MET” cohort and 73 patients in the “NED” cohort. Data from each patient were collected including age at time of prostatectomy, years of follow up, PSA levels at time of biopsy, race, lymph node status, and tumor margins. Tumor stage and Gleason score information are provided in Supplementary Table S4
Year:
2024
Collagen/ECM imaging data from TMAs comparing metastasis vs. no recurrence. A, Representative MALDI-MSI images of TMAs from metastasis (MET) category and no recurrence (NED) category. B, Segmentation analysis of 294 detected peptides. C, Volcano plot created from list of 294 detected peptides D, Heatmap of top 150 significantly different detected peptides. E, Box plot and ROC curve for 1179.5603 m / z . F, Box plot and ROC curve for 1426.6743 m / z . G, Box plot and ROC curve for 890.4250 m / z .
Year:
2024
Workflow protocols for sample preparation. For N-glycan analysis, FFPE slides were deparaffinized and rehydrated before undergoing antigen retrieval in citraconic buffer. PNGaseF (1) was applied as a “dry” molecular coating before a 2-hour incubation at 37°C. CHCA matrix was applied, and imaging of N-glycans was performed. For analysis of core- vs outer-arm fucosylated N-glycans, enzyme EndoF3 (2) was dialyzed before application, and imaging of EndoF3-digested N-glycans was performed before subsequent PNGaseF digestion and imaging of remaining N-glycans. Following glycan imaging, CHCA matrix was removed from tissues, and samples were histologically analyzed following H&E staining. Tissues underwent a second antigen retrieval with tris buffer before COLaseIII (3) was applied as a “dry” molecular coating. Slides were incubated for 5 hours at 37°C. CHCA matrix was applied, and imaging of collagen/ECM peptides was performed.
Year:
2024
Year:
2024
Year:
2024
Collaborators (9)
THOMAS HURLEY
Professor
Indiana State University
Robin Leach
Professor
-
Jonathan Gelfond
Professor
University of Texas Health Science Center at San Antonio
Matthew Gentry
Professor & Chair
University of Florida College of Medicine
Anand S. Mehta
SmartState Endowed Chair of Proteomic Biomarkers and Professor
Medical University of South Carolina
Joseph E Ippolito
Associate Professor
Washington University School of Medicine
Lauren Ball
Director, Mass Spectrometry Facility; Associate Professor
Medical University of South Carolina
Jennifer Wu
Professor
Northwestern University Feinberg School of Medicine
Richard Drake
Professor and Endowed Chair in Proteomics
Medical University of South Carolina
Make your next move.
Prepare your application
Review drafts before you send them.